Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Feb 2009

Woo Sukyung, Gardner Erin R, Chen Xiaohong, Ockers Sandra B, Baum Caitlin E, Sissung Tristan M, Price Douglas K, Frye Robin, Piekarz Richard L, Bates Susan E, Figg William D

Abstract excerpt

PURPOSE: Romidepsin is a potent histone deacetylase inhibitor under clinical development. The objective of this study was to evaluate the effect of demographic, clinical, and pharmacogenetic covariates on the pharmacokinetics of romidepsin in patients with T-cell lymphoma. EXPERIMENTAL DESIGN: Pharmacokinetic assessment was done in 98 patients enrolled in a phase II study who received 14 or 18 mg/m2 of romidepsin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to ATP Binding Cassette Transporter, Subfamily B

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Share to Depsipeptides

Share to Lymphoma, T-Cell, Cutaneous

Share to Lymphoma, T-Cell, Peripheral

Share to Models, Biological

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 19228751
DOI: 10.1158/1078-0432.CCR-08-1215
PMCID: PMC2707030

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.PMID 19228751Read ↗

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T‐cell lymphomaSemantic proximity Read ↗

Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumorsSemantic proximity Read ↗

Romidepsin for the treatment of cutaneous T-cell lymphomaSemantic proximity Read ↗

Romidepsin in peripheral and cutaneous T‐cell lymphoma: mechanistic implications from clinical and correlative dataSemantic proximity Read ↗

Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.Semantic proximity Read ↗

Phase II trial of romidepsin as consolidation therapy after gemcitabine, dexamethasone, and cisplatin in elderly transplant-ineligible patients with relapsed/refractory peripheral T- cell lymphomaSemantic proximity Read ↗

Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma.Semantic proximity Read ↗

Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma.Semantic proximity Read ↗

Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients.Semantic proximity Read ↗

Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer.Semantic proximity Read ↗

Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer.Semantic proximity Read ↗

Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.